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ABSTRACT The ﬁbronectin-binding protein A (FnBPA) is a cell surface-associated
protein of Staphylococcus aureus which mediates adherence to the host extracellular
matrix and is important for bacterial virulence. Previously, substantial sequence di-
versity was found among strains in the ﬁbrinogen-binding A domain of this protein,
and 7 different isotypes were described. The effect of this sequence diversity on the
human antibody response, in terms of both antibody production and antibody func-
tion, remains unclear. In this study, we identify ﬁve different FnBPA A domain iso-
types based on the sequence results of 22 clinical S. aureus isolates, obtained from
the same number of patients suffering from bacteremia. Using a bead-based Lu-
minex technique, we measure the patients’ total immunoglobulin G (IgG) against
the 7 FnBPA isotypes at the onset and during the time course of bacteremia (me-
dian of 10 serum samples per patient over a median of 35 days). A signiﬁcant in-
crease in IgG against the FnBPA A domain, including the isotype carried by the in-
fecting strain, is observed in only three out of 22 patients (14%) after the onset of
bacteremia. Using a Luminex-based FnBPA–ﬁbrinogen-binding assay, we ﬁnd that
preincubation of recombinant FnBPA isotypes with IgG from diverse patients does
not interfere with binding to ﬁbrinogen. This observation is conﬁrmed using an al-
ternative Luminex-based assay and enzyme-linked immunosorbent assay (ELISA).
IMPORTANCE Despite the many in vitro and murine in vivo studies involving FnBPA,
the actual presence of this virulence factor during human infection is less well estab-
lished. Furthermore, it is currently unknown to what extent sequence variation in such a
virulence factor affects the human antibody response and the ability of antibodies to in-
terfere with FnBPA function. This study sheds new light on these issues. First, the uni-
form presence of a patient’s IgG against FnBPA indicates the presence and importance of
this virulence factor during S. aureus pathogenesis. Second, the absence of an increase in
antibody production in most patients following bacteremia indicates the complexity of
S. aureus-host interactions, possibly involving immune evasion or lack of expression of
FnBPA during invasive infection. Finally, we provide new insights into the inability of hu-
man antibodies to interfere with FnBPA-ﬁbrinogen binding. These observations should
be taken into account during the development of novel vaccination approaches.
KEYWORDS Staphylococcus aureus, antibody function, antibody repertoire,
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Staphylococcus aureus can both colonize human squamous epithelial surfaces (1, 2)and cause infections that are associated with signiﬁcant morbidity and mortality,
including bacteremia (3–5). The success of S. aureus in colonizing and infecting its
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human host is attributed to many virulence factors, including surface proteins such as
the ﬁbronectin-binding protein A (FnBPA) (6). This protein is encoded by the fnbA gene
(7, 8) and is expressed by most strains of S. aureus (9). FnBPA has been shown to
contribute to disease in diverse animal models of staphylococcal infection (10–12), and
it has several functions. FnBPA promotes bacterial binding to ﬁbrinogen, elastin, and
ﬁbronectin (13–15), which are glycoproteins that are present at various concentrations
in the host extracellular matrix comprising, for instance, the mucosa and blood (16, 17).
Binding between these molecules and FnBPA mediates bacterial adhesion to and
invasion of endothelial and epithelial cells (18, 19), and it promotes bioﬁlm formation
(20, 21). The latter functions of FnBPA are considered to help S. aureus in evading
antibiotics and the host immune response (18, 19, 22).
Binding of FnBPA to ﬁbrinogen and elastin is mediated by its N-terminal A domain
(15, 23), which consists of three separately folded N1, N2, and N3 subdomains that are
structurally similar to the A domain of S. aureus clumping factor A (ClfA) and Staphy-
lococcus epidermidis serine-aspartate (SD)-repeat-containing protein G (SdrG) (24, 25).
The N2 and N3 subdomains of these surface proteins are separated by a hydrophobic
trench, and residues lining this trench are especially important in binding to ﬁbrinogen
and elastin (23).
The important role of FnBPA in S. aureus pathogenesis has made it a potentially
interesting target for vaccination approaches against this pathogen. Interference with
the interactions between FnBPA and its substrates could potentially hamper bacterial
colonization or infection of the host. However, although FnBPA has been successfully
used as a vaccine target in animal models (19, 26, 27), it has yet to be tested in humans.
Furthermore, despite promising results in animal models, targeting the functionally
similar ClfA did previously not lead to a valid vaccine in humans (28–30). Several factors
might complicate the successful use of FnBPA as a vaccine target, such as the (lack of)
presence of FnBPA during invasive infection, which, despite the plethora of studies
examining the role of FnBPA in vitro and in animal models in vivo, has been less well
established in vivo in humans. Another factor might involve the substantial sequence
diversity found in the FnBPA A domain (31), with seven different protein variants
(isotypes) identiﬁed previously sharing only 66 to 76% amino acid identity (23, 32).
Although all these isotypes bind ﬁbrinogen with similar afﬁnities, murine monoclonal
antibodies raised against different isotypes exhibit only limited cross-reactivity (32). The
effect of this sequence diversity on the human antibody response against FnBPA
remains unclear and has not been taken into account in previous vaccination studies,
including both animal models and clinical trials, nor in our previous studies character-
izing patient antibody responses (33–35). Yet if such sequence diversity in FnBPA
among clinical strains of S. aureus is present and would affect the human antibody
response, this should be taken into account during the development of future vaccines.
It is currently also unknown whether natural antibodies against FnBPA, produced in
patients after the onset of infection, can interfere with the binding between FnBPA and
ﬁbrinogen. Interestingly, it was previously shown that immunoglobulin G (IgG) ob-
tained from patients with S. aureus infections did not interfere with the binding
between ﬁbronectin and recombinant FnBPA fragments or whole S. aureus cells,
respectively (36). On the other hand, rabbit monoclonal antibodies against S. aureus
FnBP fragments did inhibit ﬁbronectin binding (37), and rabbit polyclonal antibodies
raised against clumping factor B blocked binding to ﬁbrinogen (38). Thus, the ability of
naturally occurring antibodies to block the binding between S. aureus and constituents
of the extracellular matrix remains uncertain.
The aims of this study were to further characterize sequence diversity in the A
domain of FnBPA among 22 clinical strains isolated from the blood of the same number
of patients suffering from bacteremia, to characterize the antibody responses against
different isotypes in each patient, and to ascertain the ability of human antibodies to
interfere with binding between FnBPA and ﬁbrinogen.
(This work is part of the Ph.D. thesis of P. M. den Reijer.)
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RESULTS
Variation of the FnBPA A domain in clinical S. aureus isolates. We determined
the prevalence of the seven known isotypes (I to VII) of the FnBPA A domain (23, 32)
among 22 S. aureus strains isolated from the blood of patients suffering from bacte-
remia. The FnBPA A domain of each strain was sequenced, and genomic sequences
were compared together with those of previously described reference strains for each
isotype.
In line with previous results, substantial sequence diversity was found in the FnBPA
A domain among S. aureus isolates (32). Five isotypes were identiﬁed among the 22
isolates: ﬁve strains encoded isotype I (92.7 to 100% amino acid identity to reference
strain 382), ﬁve strains encoded isotype II (96 to 100% amino acid identity to reference
strain 3011), ﬁve strains encoded isotype III (97.1 to 97.4% amino acid identity to
reference strain 182), and six strains encoded isotype IV (91.9 to 97.1% amino acid
identity to reference strain P1). One strain encoded isotype V (97.5% amino acid identity
to reference strain 3110). The genetic relationships of the fnbA A domains of all strains,
including the reference strains, are summarized in Fig. 1. Strains with the same fnbA
isotype also shared similar spa types, while the single strain encoding isotype V had spa
type t8930.
Since the isotype of the FnBPA A domain is primarily determined by the highly
divergent N2N3 subdomains (32), recombinant proteins of these subdomains were
expressed for each isotype. These proteins were covalently coupled to color-coded
beads in a Luminex setup, allowing the simultaneous quantiﬁcation of different anti-
bodies directly in serum samples to characterize patient antibody responses against
these variable subdomains.
Characterization of IgG response against FnBPA isotypes in bacteremia pa-
tients. Total IgG levels against all seven FnBPA A domain isotypes were prospectively
FIG 1 Genetic relationships of fnbA A domain between strains. fnbA gene segments encoding the entire
FnBPA A domain were sequenced from 22 clinical isolates. Numbers indicate patient number, followed by
the spa type of each strain. Sequences were aligned together with those of reference strains for the fnbA
isotypes I to VII.
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measured in serum samples from patients after the onset of bacteremia (median of 10
serum samples per patient over a median of 35 days). Although patients were infected
with a strain carrying one particular isotype, we observed that total IgG from each
patient detectably bound all seven isotypes (Fig. 2). However, the height of IgG levels,
especially against the more common isotypes I to IV and isotype V, varied considerably
between patients (Fig. 3). This is in line with the heterogeneity observed previously in
patient antibody responses after the onset of infection by our and other groups (33, 34,
39, 40).
In 18 out of 22 patients, the IgG levels directed against all isotypes did not signiﬁcantly
change after the onset of bacteremia (Fig. 2A; see Table S1 in the supplemental material),
and we could not identify a speciﬁc increase in IgG against the isotype carried by the
infecting strain. IgG levels against FnBPA did increase in the remaining four patients
after the onset of bacteremia (patients 4, 15, 17, and 20 [Table S1]). In two of these
patients, IgG levels against multiple isotypes (patient 17) or against another isotype
than that of the infecting strain (patient 20) predominantly increased. Interestingly, in
the remaining two patients (patients 4 and 15) a signiﬁcant, more-than-20-fold increase
in IgG levels predominantly against the isotype of the infecting strain was observed
(Fig. 2B; Table S1).
FnBPA isotypes bind human ﬁbrinogen. To ascertain the ability of human anti-
bodies, puriﬁed from the patients described above, to interfere with binding between
FnBPA and ﬁbrinogen, we developed a Luminex-based FnBPA–ﬁbrinogen-binding
assay. After covalently coupling recombinant FnBPA isotype proteins to beads, we
conﬁrmed that all seven isotypes were able to bind R-phycoerythrin (R-PE)-labeled
FIG 2 Course of IgG levels against FnBPA isotypes following bacteremia. (A) Representative course of IgG levels against 7 FnBPA isotypes
(I to VII) following the onset of bacteremia (day 0, deﬁned as the day of the ﬁrst blood culture positive for S. aureus) in patient 1, infected
with a strain carrying isotype II. (B) Same plot for patient 15, infected with a strain carrying isotype V. Data points represent the mean for
two separate measurements per serum sample.
FIG 3 Variation in peak IgG levels against FnBPA isotypes after the onset of bacteremia. Scatter plot
showing the distribution of peak IgG levels against all 7 FnbPA isotypes (I to VII) in 22 patients suffering
from bacteremia. Each point represents one patient, and horizontal lines represent the medians and
interquartile ranges.
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human ﬁbrinogen in a dose-dependent and saturable manner (Fig. S1A). This binding
was further conﬁrmed by a competition assay using R-PE-labeled and unlabeled
ﬁbrinogen, showing that the amount of bound PE-labeled ﬁbrinogen decreased at
increasing concentrations of unlabeled ﬁbrinogen (Fig. S1B). Speciﬁc binding of ﬁbrin-
ogen by the FnBPA isotypes was conﬁrmed by the lack of ﬁbrinogen binding observed
for the SD-repeat-containing protein E (SdrE) and iron-responsive surface determinant
A (IsdA), which have low to no afﬁnity for ﬁbrinogen (41).
Human IgG does not inhibit binding between FnBPA isotypes and ﬁbrinogen.
Next, we investigated if puriﬁed IgG, isolated from bacteremia patients, could interfere
with the binding between the FnBPA isotypes and ﬁbrinogen. We conﬁrmed that total
IgG puriﬁed from ﬁve different patients, each infected with a strain carrying a different
FnBPA isotype, and from polyclonal human IgG (PHG), obtained from noninfected
volunteers, bound FnBPA isotypes I to V in a speciﬁc and dose-dependent manner
(Fig. S2A and B). Human IgG did not notably bind to ﬁbrinogen (data not shown).
After preincubation of FnBPA isotypes I to V with the IgG from either PHG or
patients, resulting FnBPA-bound IgG was allowed to bind PE-labeled ﬁbrinogen. Based
on results as shown in Fig. S1A, we chose a standard concentration of 1 g PE-labeled
ﬁbrinogen per reaction mixture. Preincubation of FnBPA isotypes I to V with IgG from
either PHG or patients did not interfere with the binding of this protein to PE-labeled
ﬁbrinogen, regardless of the IgG dilution (Fig. 4A and B). The amount of ﬁbrinogen
bound by the isotypes after preincubation with IgG dilutions did not signiﬁcantly differ
from controls without preincubation with IgG (one-way analysis of variance [ANOVA],
signiﬁcance level of P  0.05). Varying the starting concentration of ﬁbrinogen did not
affect these results, nor did simultaneous incubation of ﬁbrinogen, IgG, and FnBPA
isotypes (data not shown).
To rule out the possibility that the coupling of FnBPA isotypes to the xMAP beads
could somehow affect protein structure and thereby alter binding sites for IgG, which
could alternatively explain the lack of interference by IgG as described above, we
performed two alternative assays. In the ﬁrst (Luminex-based) assay, ﬁbrinogen coupled
to beads was incubated with PE-labeled, free recombinant isotypes II and III. We
conﬁrmed a dose-dependent and saturable binding between the free FnBPA isotypes
and immobilized ﬁbrinogen (data not shown). Subsequently, we preincubated the free
isotypes II and III with IgG from PHG or from one of the patients, followed by incubation
with the immobilized ﬁbrinogen. In line with the results described above, ﬁbrinogen
binding by both isotypes was not inhibited by any dilution of IgG (Fig. 5A). The amount
of bound PE-labeled FnBPA after preincubation with IgG did not signiﬁcantly differ
from controls without preincubation with IgG (one-way ANOVA, signiﬁcance level of
P  0.05).
FIG 4 Preincubation of FnBPA isotypes with human IgG does not prevent binding of ﬁbrinogen. (A) The most common
isotypes, I to V, coupled to beads, were preincubated in this Luminex assay with a dilution range of IgG puriﬁed from
polyclonal human IgG (PHG). Binding of a ﬁxed concentration of PE-labeled ﬁbrinogen was then measured. (B) Results of
the same experiment using dilution ranges of IgG puriﬁed from different patients. Each isotype was preincubated with IgG
from a patient who was infected with a strain carrying that isotype (e.g., patient 19 was infected with a strain carrying
isotype I).
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The results described above were further conﬁrmed using enzyme-linked immu-
nosorbent assay (ELISA), wherein isotypes I and V were immobilized onto 96-well plates
and incubated with ﬁbrinogen. Again, preincubation of both isotypes with a concen-
tration range of IgG from either PHG or patients did not affect the amount of bound
ﬁbrinogen (Fig. 5B). As a control, we incubated ﬁbrinogen with an increasing concen-
tration of recombinant clumping factor A (ClfA) of S. aureus, which also binds to the
same site on the ﬁbrinogen r-chain as FnBPA, and measured the binding of ﬁbrinogen
to immobilized FnBPA. As expected, ClfA inhibited ﬁbrinogen binding to FnBPA
(Fig. 5C).
DISCUSSION
We found that most patients suffering from serious invasive S. aureus infections do
not respond to the microbial challenge by increasing production of preexisting IgG
antibody titers directed against the A domain of the most common FnBPA isotypes,
including the isotype carried by the infecting strain. Only 3 out of 22 patients (14%)
mounted a signiﬁcantly increased antibody response against FnBPA after the onset of
bacteremia, which was predominantly directed against the isotype of the infecting
strain in two patients. The immunoglobulins obtained from these and other patients, as
well as from healthy volunteers, were not able to interfere with the binding between
FnBPA and human ﬁbrinogen in vitro.
In line with previous results, we found that fnbA isotypes I to IV were the most
common among clinical isolates (32). Total IgG from patients could detectably bind
FIG 5 Conﬁrmation of the inability of human IgG to prevent binding between FnBPA isotypes and ﬁbrinogen. (A)
PE-labeled, free FnBPA isotypes II and III were preincubated with a dilution range of total IgG either from PHG or
from patients 14 and 18 (who were infected with strains carrying isotypes II and III, respectively). Protein-antibody
complexes were then allowed to bind ﬁbrinogen coupled to Luminex beads. (B) Using an alternative ELISA,
preincubation of ﬁbrinogen with IgG from patient 15 (infected with a strain carrying isotype V) did not clearly affect
subsequent binding to coated FnBPA isotype V. Similar results were obtained for isotype I (data not shown). (C)
Using the same ELISA, preincubation with ClfA, instead of IgG, inversely decreased the amount of remaining
ﬁbrinogen bound to FnBPA isotype V. All data points represent the mean for two measurements and are expressed
as median ﬂuorescence intensity (MFI) for panel A or as optical density at 450 nm for panels B and C.
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these isotypes and was ubiquitously present at the onset of bacteremia. First, this
ubiquitous presence of IgG against FnBPA suggests an important role of this virulence
factor in the pathogenesis of S. aureus, presumably during colonization of the host and
the early stages of infection. This is in line with the importance attributed to FnBPA
during bacterial attachment, colonization, and infection in previously described in vitro
and in vivo animal models (6, 11, 12).
Second, our results shed new light on the human antibody response toward FnBPA.
Preexisting IgG levels that were detected at the onset of bacteremia against all
isotypes—including that of the infecting strain—did not notably change during the
course of infection in 18 out of 22 patients. This is in line with our previous results
obtained with the same sera, showing that most virulence factors of S. aureus do not
induce uniform increases in antibody titers after the onset of bacteremia (33). Notably,
these patients were not immunosuppressed at the time of infection, and some viru-
lence factors did induce a signiﬁcant antibody response. Why other virulence factors,
including FnBPA, do not uniformly induce a signiﬁcant antibody response upon infec-
tion is currently unknown. Possibly, active manipulation of the host adaptive immune
response by S. aureus plays a role (42, 43), or perhaps immunogenic epitopes of the
FnBPA A domain are normally not exposed to the host adaptive immune system during
infection due to the many interactions of this protein with host extracellular proteins
(44). Finally, it could be that FnBPA is expressed only infrequently on the surface of
S. aureus during the course of bacteremia, although fnbA mRNA was detectable
during in vitro bacterial growth in human blood in our previous study (33).
Interestingly, of the three patients who did mount a signiﬁcant antibody response
against FnBPA, one patient was infected with a strain carrying the rare isotype V.
Although speculative, perhaps this isotype is associated with less-effective immune
manipulation, more immunogenic exposure toward the host, and/or higher expres-
sion during bacteremia.
We currently do not know to what extent circulating antibodies differ in speciﬁcity
for the different isotypes. On one hand, as opposed to the limited cross-reactivity
observed previously for murine monoclonal antibodies raised against different isotypes
(32), natural human polyclonal antibodies might possess cross-reactivity for different
isotypes. This would be in line with our previous ﬁndings, wherein the same patient IgG
was found to cross-react between the structurally similar leukocidin and gamma-
hemolysin toxin components (33). Cross-reactivity could explain the simultaneous rise
in IgG against multiple isotypes that was observed in two patients. On the other hand,
the observation of de novo antibody production speciﬁcally against the isotype carried
by the infecting strain in one patient suggests that speciﬁc, non-cross-reacting anti-
bodies may be present as well.
The functionality of antibodies against FnBPA remains another subject of debate.
Although data from antibodies raised in animal models suggest that they do block
binding between S. aureus surface proteins and ﬁbronectin (37, 38, 45), other studies,
including those with human antibodies, do not show any interference with binding to
ﬁbronectin (36, 46). Our results are in line with the latter, demonstrating no apparent
effect at any dilution of human IgG, puriﬁed from multiple patients, even from those
with a signiﬁcant antibody response against the isotype carried by the infecting strain,
on binding between ﬁbrinogen and FnBPA. A molecular explanation for this observa-
tion is currently lacking. Possibly, FnBPA binds with higher afﬁnity to ﬁbrinogen than to
antibodies, or the two ligands have different binding sites on FnBPA. Alternatively, the
functional binding domains within FnBPA remain immunologically hidden until the
ligand is bound (36), or ligand binding might induce conformational changes leading
to the exposition of other, nonfunctional binding sites for antibodies. The presence of
these ligand-induced binding site (LIBS) antibodies against FnBPA has been demon-
strated in patients suffering from S. aureus endocarditis (47). Finally, it has even been
suggested that antibody binding might stabilize the interaction between FnBPA and
ﬁbrinogen (36), thereby actually enhancing binding, as observed for the binding of
Streptococcus dysgalactiae FnBA to ﬁbronectin when preincubated with mouse anti-
FnBPA-Speciﬁc Human IgG and Fibrinogen
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bodies (46). Antibodies against FnBPA could have other functions than interfering with
ligand binding. For instance, antibodies can assist in the opsonization of S. aureus (48)
or in augmenting microbicidal killing by phagocytes (49).
We conﬁrmed the inability of IgG to block FnBPA-ﬁbrinogen binding with three
alternative assays, to rule out that the coupling of either protein to xMAP beads could
somehow affect correct antibody binding, for instance, due to conformational changes.
Of note is that the measured median ﬂuorescence intensities (MFIs) in the Luminex
assay were much higher when free PE-labeled FnBPA isotypes were used instead of
PE-labeled ﬁbrinogen. Possibly, the large size of ﬁbrinogen (50) would allow only a few
PE-labeled molecules to bind to FnBPA-coated beads, while conversely, relatively many
smaller PE-labeled FnBPA proteins could bind to ﬁbrinogen-coated beads. Alternatively,
the efﬁcacies of coupling of the two proteins to beads might differ. We currently do not
know what the efﬁcacies of the coupling reactions are; however, even if coupling
efﬁciencies differ, the interpretation of our inhibition experiments remains unchanged.
With regard to the suitability of FnBPA as a vaccine target, our results can be
interpreted twofold. On one hand, we and others found that FnBPA-speciﬁc IgG is
already circulating prior to the onset of clinical infection, probably resulting from
multiple prior exposures to S. aureus, and yet this immune state does not confer
protection from clinical disease (31, 33, 51, 52). Furthermore, the inability of human IgG
to block binding between FnBPA and ﬁbrinogen would argue against the use of FnBPA
as a vaccine target. On the other hand, future vaccination approaches based on
recombinant protein variants of FnBPA might induce novel, more protective anti-
bodies against functionally important epitopes that are not normally targeted by
the humoral immune response. This rationale is supported by previous work demonstrating
that serum from unvaccinated human subjects was unable to block the interaction
between S. aureus clumping factor A (ClfA) and ﬁbrinogen, while antibodies elicited by
a recombinant ClfA-containing vaccine could block this binding (53). Moreover, the level of
functional antibody titers, able to block ClfA-ﬁbrinogen binding in vitro, could directly be
correlated with protection against S. aureus infection in an animal model in vivo (54). In this
light, our results conﬁrming the lack of functional antibodies against FnBPA in natural
human sera, unable to protect against bacteremia, do not argue against the suitability of
FnBPA as a vaccine target. In fact, our results might suggest that there is a window of
opportunity for inducing novel, functionally interfering antibodies that can confer protec-
tion against invasive S. aureus infection.
To conclude, our results encourage further exploration into novel vaccination
approaches that target the ubiquitously present FnBPA protein of S. aureus. Especially,
further studies into the speciﬁc interactions between the FnBPA A domain and human
antibodies, and their functional consequences, are needed.
MATERIALS AND METHODS
Ethics statement. All patient serum samples used in this study were obtained from coded leftover
material from routine diagnostic blood samples. In accordance with the guidelines of the Erasmus
University Medical Center (MC) and the Dutch Federation of Biomedical Scientiﬁc Societies (Federatie van
Medische Wetenschappelijke Verenigingen), all Erasmus MC patients are routinely informed of the
possibility that leftover material from diagnostic samples may be used, albeit anonymously, for scientiﬁc
research; all patients are routinely offered the opportunity to opt out in writing. Serum samples used in
this study were obtained only from patients who did not object to the use of leftover material for
scientiﬁc research and, in addition, gave verbal consent. This procedure was approved and the acqui-
sition of additional written consent was waived speciﬁcally for this retrospective study by the Medical
Ethics Committee of the Erasmus University Medical Center Rotterdam (MEC-2007-106, addendum 2). All
serum samples were coded, and only qualiﬁed physicians of the Department of Medical Microbiology
and Infectious Diseases had access to the original patient data.
Bacterial strains and patients. Serum samples and S. aureus isolates were obtained from 22 patients
diagnosed with bacteremia, as described previously (33). In brief, bacteremia was deﬁned as the isolation
of S. aureus from at least one blood culture set. Starting from the ﬁrst positive blood culture, a median
number of 10 (interquartile range [IQR], 5 to 17) serum samples were collected per patient over a median
period of 34.5 (interquartile range, 15 to 50) days.
Sequencing of fnbA A domains. DNA was isolated from strains using the QIAamp DNA minikit
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. The A domain of fnbA genes was
ampliﬁed by PCR using previously described ﬂanking primers (32) minus the restriction sites. Products
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resulting from ampliﬁcations were sequenced using a 3100 ABI Prism genetic analyzer (Applied Biosys-
tems, Nieuwerkerk a/d IJssel, The Netherlands). Based on sequences of the ﬂanking regions, individual
primer sets were designed for each strain (sequences available upon request), and these were used to
amplify and sequence the remaining part of each A domain. Overlapping sequences were merged for
each strain and aligned with publicly available reference sequences of all FnBPA isotypes, which have
been described previously (32). The complete sequences of all strains are available upon request. Primer
design and alignments were performed using Primer-BLAST (available at https://www.ncbi.nlm.nih.gov)
and MegAlign software (DNAStar Inc., Madison, WI, USA), respectively.
Expression of recombinant FnBPA isotype proteins. pQE30 constructs expressing His-tagged
N2N3 A domains of isotypes I to VII were kindly provided by T. Foster (32). Each construct was veriﬁed
by sequencing using pQE30-speciﬁc primers (sequence available upon request). Constructs were trans-
formed into Escherichia coli Top 10, expressed by induction with isopropyl--D-1-thiogalactopyranoside
(IPTG), and puriﬁed under denaturing conditions with nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qia-
gen, Valencia, CA) according to the instructions of the manufacturer (QIAexpressionist handbook).
Resulting proteins were quality controlled by SDS-PAGE and dialyzed against phosphate-buffered saline
(PBS) for 24 h at 4°C.
Measurement of antibodies. IgG levels against all recombinant N2N3 A domains of FnBPA isotypes
in the serum samples of bacteremia patients were measured using a bead-based ﬂow cytometry
technique (xMAP; Luminex Corporation, Austin, TX), as previously described (33). Brieﬂy, recombinant
proteins constituting the N2N3 A domains of FnBPA isotypes were covalently coupled to carboxy-
lated xMAP beads, which were activated with N-hydroxysulfosuccinimide (sulfo-NHS) and 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) according to a previously optimized protocol (55).
Protein-coated beads were then incubated with human serum which was diluted 1:100 in PBS. After
repeated washing with PBS, bound antibodies were quantiﬁed using a 1:200 dilution of secondary
phycoerythrin (PE)-labeled goat anti-human IgG antibodies. All measurements were performed in
duplicate, and the median ﬂuorescence intensities (MFIs), a semiquantitative measure of antibody levels,
were averaged. Eighty-nine out of 1,827 duplicate measurements (0.05%) had coefﬁcients of variation
larger than 25% and were excluded from further analysis. All measurements were corrected for
nonspeciﬁc background signal by subtracting the MFIs of control beads not coupled to any protein. The
course of IgG levels over time was assessed graphically, and initial-to-peak increases in IgG levels were
calculated for all isotypes in each patient. A more-than-4-fold initial-to-peak increase in IgG within
2 weeks after the onset of bacteremia was considered proof of a signiﬁcant immune response.
Luminex-based FnBPA–ﬁbrinogen-binding assay. Recombinant FnBPA isotypes and the non-
ﬁbrinogen-binding surface proteins SdrE and IsdA were coupled to xMAP beads as described above.
Human ﬁbrinogen (Calbiochem, Merck, Darmstadt, Germany) was labeled with phycoerythrin (PE) using
the Lightning-Link R-PE conjugation kit (Innova Biosciences, Cambridge, United Kingdom) according to
the manufacturer’s protocol, starting with 15 mg ﬁbrinogen per 10 ml of 50 mM 2-(N-morpholino)-
ethanesulfonic acid (MES) buffer. Protein-coated xMAP beads were incubated with various concentra-
tions of PE-labeled ﬁbrinogen, and after washing with PBS-1% bovine serum albumin (BSA), median
ﬂuorescence intensities (MFIs) were determined as a measure of bound ﬁbrinogen using the same
bead-based ﬂow cytometry technique as described above. To study the effect of potentially interfering
antibodies, total IgG was puriﬁed from sera of 5 different bacteremia patients and from pooled serum
obtained from healthy volunteers (polyclonal human IgG [PHG]) using a HiTrap Protein G HP 1-ml column
(GE Healthcare, Fairﬁeld, CT) according to the manufacturer’s protocol. Puriﬁed IgG was dialyzed against
PBS for 24 h at 4°C, and resulting antibody concentrations were 4.7 mg/ml for PHG and a median of
5.1 mg/ml (interquartile range [IQR], 4.4 to 8.8 mg/ml) for patient sera. Bead-bound isotypes were
preincubated with a dilution range of the puriﬁed IgG, washed with PBS-1% BSA, and then incubated
with a standard concentration of 1 g PE-labeled ﬁbrinogen per reaction mixture.
For the alternative Luminex-based binding assay, ﬁbrinogen was coupled to beads and recombinant
proteins of FnBPA isotypes II and III were PE labeled as described above. Free FnBPA isotypes were
preincubated with puriﬁed IgG and then incubated with the ﬁbrinogen-coated beads according to the
protocol described above. All binding assays were repeated separately twice, and ﬁgures present the
means for these measurements.
ELISA-based FnBPA–ﬁbrinogen-binding assay. An enzyme-linked immunosorbent assay (ELISA)
was performed to further conﬁrm FnBPA-ﬁbrinogen binding as previously described (56). In brief, 96-well
Immulon 4HBX microtiter plates (Thermo Scientiﬁc, Waltham, MA) were coated overnight at 4°C and with
gentle rotation with 0.5 g per well of FnBPA isotypes, diluted in PBS. After blocking the wells with 2%
BSA in PBS, plates were washed once with Tris-buffered saline (TBS) and coated isotypes were preincu-
bated with a concentration range of puriﬁed IgG, diluted in TBS, for 1 h at room temperature.
Subsequently, after 3 additional wash steps with TBS plus 0.1% Tween, plates were incubated for another
hour with a ﬁxed concentration of 40 nM ﬁbrinogen (diluted in TBS). After another 3 wash steps, the
bound ﬁbrinogen was detected through incubation with horseradish peroxidase (HRP)-conjugated
antiﬁbrinogen antibodies (1:10,000 dilution) (Thermo Scientiﬁc) for 1 h and quantiﬁed after adding the
substrate o-phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich). The resulting absorbance at 450
nm (optical density [OD] at 450 nm) was measured in an ELISA microplate reader (Thermomax).
In the case of the ClfA competition assay, 40 nM ﬁbrinogen was preincubated for 1 h with a 2-fold
concentration range of recombinant ClfA (40 to 0.625 M) and then incubated with FnBPA isotype-
coated plates as described above.
Statistical analysis. Fold increases in antibody levels were calculated as the ratio of the peak
antibody level divided by the initial antibody level (as measured in the ﬁrst serum sample). One-way
FnBPA-Speciﬁc Human IgG and Fibrinogen
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ANOVA with the duplicate measurements of bound PE-labeled ﬁbrinogen (or FnBPA isotypes) as
dependent variables and the IgG dilutions as factor were used to determine the signiﬁcance of any
differences in bound protein between different IgG dilutions. P values of 0.05 were considered
statistically signiﬁcant. IBM SPSS Statistics version 21 (IBM Corporation, Armonk, NY) was used for
statistical analysis. Graphics were made using GraphPad Prism version 5 (GraphPad Inc., La Jolla, CA).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00590-17.
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